Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palovarotene for preosseous flare-ups in fibrodysplasia ossificans progressiva
2014-001453-17Phase 2Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing Palovarotene with Placebo (2 arms). Primary endpoint: Responder rate at Day 42. Started Feb 2015; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2014-001453-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001453-17.